RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于抗体-细胞偶联的研究进展
英文原题：Advances in research based on antibody-cell conjugation.
查看英文原题
Advances in research based on antibody-cell conjugation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
抗体-细胞偶联（ACC）技术是近年来医学和生物技术领域的一个新研究方向。ACC的概念由Hsiao等人提出，并发展成为一种可行的细胞治疗技术，其是指将具有特定功能的细胞，如NK 细胞（NK细胞）、细胞因子诱导的杀伤细胞（CIK）等免疫细胞与单克隆抗体通过连接体共同形成的偶联物。ACC通过简单有效的化学偶联方法直接在细胞表面修饰特异性抗体，使细胞具有新的功能。ACC已被开发用于治疗多种疾病，包括血液系统癌症和实体瘤。本文综述了目前ACC的构建方法、面临的挑战及未来的发展方向。
展开英文摘要原文
Antibody-cell conjugation (ACC) technology is a new research direction in medicine and biotechnology in recent years. The concept of ACC was proposed by Hsiao et al. and developed into a viable cell therapy technology, which refers to the cells with specific functions. Such as natural killer cells (NK cells), cytokine induced killer cells (CIK) and other immune cells and monoclonal antibodies through the linker together formed conjugate.
ACC directly modifies specific antibodies on the cell surface through a simple and effective chemical coupling method to enable cells to have new functions. ACC has been developed for the treatment of various diseases, including cancers of the blood system and solid tumors. This paper reviews the current ACC construction methods, challenges and future development directions.
论文信息
- 作者
- Ma X、Jiang J、An X、Zu W、Ma C、Zhang Z、Lu Y、Zhao L
- 单位
- Department of Rehabilitation, School of Nursing, Jilin University, Changchun, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2023
- 原文标识
- PubMed 38162639 · DOI 10.3389/fimmu.2023.1310130
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →